Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Ovarian Neoplasms 4Breast Neoplasms 2Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Epithelial Cancer Recurrent 1Lymphoma 1

Interventions

Psychiatric Rehabilitation 7Flow Cytometry 6Therapeutics 5Surveys and Questionnaires 5Microarray Analysis 5Gene Expression Profiling 5Vincristine 4Polymerase Chain Reaction 4Methotrexate 4Daunorubicin 4Cytogenetic Analysis 4Amplified Fragment Length Polymorphism Analysis 4ponatinib 3fludarabine 3Watchful Waiting 3Prednisone 3Observation 3Mercaptopurine 3Interviews as Topic 3Inotuzumab Ozogamicin 3Immunologic Techniques 3Immunoenzyme Techniques 3Cytarabine 3Cyclophosphamide 3tisagenlecleucel 2pegaspargase 2fish oil triglycerides 2blinatumomab 2In Situ Hybridization, Fluorescence 2Imatinib Mesylate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Precursor Cell Lymphoblastic Leukemia-Lymphoma × liposomal doxorubicin × Clear all
NCT03419494 2018-02-05

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown
40 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡